Sukru Tuzmen

List of Publications by Year
in descending order

29 papers	**731** citations
759190 **12** h-index	713444 **21** g-index
32 all docs	**32** docs citations
32 times ranked	**1377** citing authors

#	Article	IF	Citations
1	Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nature Genetics, 2004, 36, 979-983.	21.4	180
2	An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer. Oncogene, 2012, 31, 2090-2100.	5.9	111
3	Intersex-like (IXL) Is a Cell Survival Regulator in Pancreatic Cancer with 19q13 Amplification. Cancer Research, 2007, 67, 1943-1949.	0.9	68
4	Functional evidence implicating S100P in prostate cancer progression. International Journal of Cancer, 2008, 123, 330-339.	5.1	61
5	Genetic diseases of hemoglobin: diagnostic methods for elucidating β-thalassemia mutations. Blood Reviews, 2001, 15, 19-29.	5.7	36
6	Human SNPs resulting in premature stop codons and protein truncation. Human Genomics, 2006, 2, 274.	2.9	36
7	Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran. Pharmacogenomics and Personalized Medicine, 2017, Volume 10, 267-278.	0.7	35
8	Site-Directed Mutagenesis. Methods in Molecular Biology, 2011, 700, 107-124.	0.9	28
9	PRENATAL DIAGNOSIS OF β-THALASSAEMIA AND SICKLE CELL ANAEMIA IN TURKEY. , 1996, 16, 252-258.		21
10	Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine. Human Mutation, 2008, 29, 461-467.	2.5	18
11	Characterization of farnesyl diphosphate farnesyl transferase 1 (*FDFT1*) expression in cancer. Personalized Medicine, 2019, 16, 51-65.	1.5	17
12	Differential subcellular expression of protein kinase C betaII in breast cancer: correlation with breast cancer subtypes. Breast Cancer Research and Treatment, 2010, 124, 327-335.	2.5	16
13	NCI60 Cancer Cell Line Panel Data and RNAi Analysis Help Identify EAF2 as a Modulator of Simvastatin and Lovastatin Response in HCT-116 Cells. PLoS ONE, 2011, 6, e18306.	2.5	15
14	A Novel Deletion in a Turkish β-Thalassewia Patient Detected by DGGE and Direct Sequencing: FSC 22–24 (-7 bp). Hemoglobin, 1993, 17, 387-391.	0.8	14
15	Validation of Short Interfering RNA Knockdowns by Quantitative Real-Time PCR. , 2007, 353, 177-204.		13
16	Reasoning on Scientific Workflows. , 2009, , .		12
17	Genotype-Phenotype Analysis in HbS-Beta-Thalassemia. Human Heredity, 1997, 47, 161-164.	0.8	10
18	Patisiran for the treatment of patients with familial amyloid polyneuropathy. Drugs of Today, 2019, 55, 315.	1.1	9

#	Article	IF	Citations
19	Validation of signalling pathways: Case study of the p16-mediated pathway. Journal of Bioinformatics and Computational Biology, 2015, 13, 1550007.	0.8	8
20	RNAi-Based Functional Pharmacogenomics. Methods in Molecular Biology, 2011, 700, 271-290.	0.9	7
21	Techniques for Nucleic Acid Engineering. , 2018, , 247-315.		5
22	Rare Î²-thalassemia mutation IVS-II-848 (C-A) first reported in a Turkish cypriot family. , 1997, 54, 338-339.		3
23	Genetic Predisposition to Î²-Thalassemia and Sickle Cell Anemia in Turkey: A Molecular Diagnostic Approach. Methods in Molecular Biology, 2011, 700, 291-307.	0.9	3
24	Target-based drug discovery for Î²-globin disorders: drug target prediction using quantitative modeling with hybrid functional Petri nets. Journal of Bioinformatics and Computational Biology, 2016, 14, 1650026.	0.8	2
25	Blood contact properties of ascorbyl chitosan. Journal of Biomaterials Science, Polymer Edition, 2013, 24, 1969-1987.	3.5	1
26	Molecular and population genetic analyses of Î²â€Thalassemia in Turkey. American Journal of Hematology, 1998, 57, 215-220.	4.1	1
27	Designing and Implementing Pharmacogenomics Study. , 2013, , 97-122.		1
28	Abstract 4023: ARID1A is a candidate tumor suppressor gene in breast cancer. , 2011, , .		0
29	Potential Therapeutic Modalities of Reawakening Fetal Hemoglobin Simulated by Reaction Systems. Acta Polytechnica Hungarica, 2019, 16, .	2.9	0